Ebglyss FDA approval intensifies competition in atopic dermatitis market

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s (NYSE: LLY) Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market alongside therapies like LEO Pharma’s Adtralza (tralokinumab) and Sanofi’s (Euronext: SAN) Dupixent (dupilumab).

Although there are current treatment options ranging from topical therapies to systemic treatments  there is a significant unmet need remains for safer and more effective long-term AD therapies, which may further be addressed by this new approval in the USA, says pharma analytics company GlobalData.

Filippos Maniatis, GlobalData’s healthcare analyst, comments: “Ebglyss offers a therapeutic option for AD patients, who have had limited success with existing treatments in the US. Ebglyss’ pivotal clinical trials, ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967), have demonstrated its therapeutic efficacy in reducing the signs and symptoms of AD and its tolerance. Ebglyss is expected to become one of the competitors of other therapies with similar mechanisms of action (MoAs), such as Sanofi/Regeneron’s Dupixent (dupilumab) and LEO Pharma’s Adbry/Adtralza (tralokinumab).”